河化股份(000953) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥24,691,165.08, a decrease of 57.87% compared to the same period last year[7]. - Total operating revenue for Q1 2019 was ¥24,691,165.08, a decrease of 57.9% compared to ¥58,610,702.46 in the same period last year[34]. - The net profit attributable to shareholders was -¥16,377,829.62, an improvement of 58.48% year-on-year[7]. - The net loss for Q1 2019 was ¥16,377,829.62, an improvement from a net loss of ¥39,449,836.81 in Q1 2018[36]. - The company's operating revenue for the current period is ¥2,062,695.15, a significant decrease from ¥30,602,865.72 in the previous period, representing a decline of approximately 93.3%[39]. - Operating profit for the current period is reported at -¥16,120,626.81, an improvement compared to -¥40,131,260.26 in the previous period, indicating a reduction in losses by about 59.8%[39]. - The net profit for the current period stands at -¥16,110,626.81, which is also an improvement from -¥40,103,968.20 in the previous period, reflecting a decrease in losses of approximately 59.9%[40]. - Basic and diluted earnings per share for Q1 2019 were both -¥0.0557, compared to -¥0.1342 in the same period last year[37]. - The basic and diluted earnings per share for the current period are both -¥0.0548, an improvement from -¥0.1364 in the previous period, reflecting a reduction in loss per share by about 60%[40]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥4,618,044.93, showing an increase of 87.31% compared to the previous year[7]. - Cash flow from operating activities shows a net outflow of -¥4,618,044.93, which is an improvement from -¥36,385,058.15 in the previous period, indicating a reduction in cash outflow by about 87.3%[43]. - The company's cash and cash equivalents decreased by 46.43% to ¥2,357,700, primarily due to cash outflows from operating activities[14]. - The total cash and cash equivalents at the end of the period is ¥2,719,998.67, down from ¥8,360,357.35 in the previous period, a decrease of approximately 67.5%[44]. - The company received cash from other operating activities amounting to ¥2,271,734.77, a significant increase from ¥236,476.47 in the previous period, representing an increase of about 862.5%[43]. - The company reported cash inflow from financing activities of ¥2,150,000.00, a decrease from ¥28,500,000.00 in the previous period, indicating a decline of approximately 92.5%[44]. - The net increase in cash and cash equivalents was -178,636,046.38 CNY[47]. - The ending balance of cash and cash equivalents was 1,455,896.23 CNY[47]. Assets and Liabilities - The total assets at the end of the reporting period were ¥415,900,080.52, an increase of 7.42% from the end of the previous year[7]. - As of March 31, 2019, the company's total assets amounted to CNY 415.90 million, an increase from CNY 387.18 million as of December 31, 2018, representing a growth of approximately 7.0%[26]. - The company's total liabilities increased to CNY 681.57 million from CNY 636.99 million, marking an increase of approximately 7.0%[28]. - The company's total assets decreased to ¥361,318,385.12 from ¥371,310,273.03 at the end of the previous period[33]. - Total liabilities increased slightly to ¥630,603,443.89 from ¥624,995,959.43[33]. - The owner's equity showed a deficit of ¥269,285,058.77, worsening from a deficit of ¥253,685,686.40[33]. - The company's equity attributable to shareholders was reported at CNY -265.67 million, worsening from CNY -249.80 million at the end of 2018[30]. Inventory and Prepayments - The company reported a significant increase in prepayments, which rose by 1,106.14% to ¥421,310,000, mainly due to payments to suppliers[14]. - The company reported a significant increase in prepayments, which rose to CNY 45.94 million from CNY 3.81 million, a growth of approximately 1,105.0%[26]. - The company’s inventory decreased by 12.62% to ¥238,790,000, attributed to sales of inventory goods[14]. - Inventory decreased to CNY 16.53 million from CNY 18.92 million, a reduction of about 12.6%[26]. Shareholder Information - The company’s major shareholders include Ningbo Yinyi Holdings Co., Ltd. with a 29.59% stake and Guangxi Hechi Chemical Industry Group Co., Ltd. with a 12.75% stake[10]. Corporate Actions - The company plans to acquire control of Chongqing Nansong Pharmaceutical Technology Co., Ltd., which constitutes a major asset restructuring[15]. - The company’s stock was placed under "delisting risk warning" due to negative net assets as of the end of 2018[15]. Expenses and Other Income - Total operating costs for Q1 2019 were ¥41,278,155.43, down 58.0% from ¥98,036,522.48 year-on-year[34]. - The company reported a significant reduction in management expenses, which were ¥10,988,794.25, up from ¥7,702,316.06 in the previous year[34]. - The management expenses for the current period are reported at ¥10,826,927.89, an increase from ¥7,656,212.48 in the previous period, representing an increase of about 41.5%[39]. - Other income for Q1 2019 was ¥199,160.73, unchanged from the previous year[34]. - The company recorded a financial expense of ¥6,082,469.13, slightly down from ¥6,168,084.37 year-on-year[34]. - The company incurred sales expenses of ¥183,600.75, down from ¥41,544.67 in the previous period, indicating a decrease of approximately 56.1%[39]. Investment and Derivatives - The company had no significant non-operating fund occupation by controlling shareholders or related parties during the reporting period[22]. - There were no derivative investments reported during the period, indicating a conservative investment strategy[19]. Audit and Standards - The first quarter report was not audited[49]. - The company did not apply new financial instrument standards or new revenue standards[48].